HENDERSON, Nev., Sept. 11,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some
of the world's leading experts in sepsis to explore the potential
of using Volition's Nu.Q® NETs technology effectively in clinical
practice.
The roundtable event was chaired by Professor Djillali Annane, Professor of Medicine at
University Paris Saclay-UVSQ.
Professor Annane, said: "The need for improvements in sepsis
management and patient outcomes is clear. Sepsis kills over 11
million people worldwide each year, and approximately half of those
who survive the disease are left with devastating, long-term
physical and psychological effects. Early detection and management
of sepsis has the potential to reduce mortality and improve the
quality of life of survivors.
"We brought together experts in sepsis from across the globe to
share research findings from several large independent studies, and
consider how Volition's Nu.Q® NETs technology could be introduced
in clinical practice.
"It was clear from our roundtable discussion and confidential
data review that Nu.Q® NETs has the potential to predict organ
failure, for example, acute kidney injury in patients with
infection and therefore could be used to enhance sepsis
management."
Nu.Q® NETs, Volition's nucleosome quantification technology, is
a simple, low-cost, accessible test that quantifies an individual's
level of circulating H3.1 nucleosomes in the bloodstream, a
surrogate marker for Neutrophil Extracellular Traps (NETs).
Although NETs play a critical role in our normal immune response,
elevated levels of NETs can lead to tissue damage, and in severe
cases, sepsis, organ failure and death.
Dr Andrew Retter, Chief Medical
Officer at Volition, said: "Volition is collaborating closely with
KOLs and centers of excellence worldwide, and we are delighted to
have hosted such an esteemed roundtable event. With a range of
publications pending, we look forward to sharing latest findings at
our upcoming satellite symposium, taking place at ESICM in
Barcelona on Monday 7th
October 2024."
Chaired by Professor Djillali Annane Volition's KOL event
comprised:
- Professor Derek Angus, Professor
and Chair of the Critical Care Medicine Department at the
University of Pittsburgh. Professor
Angus is a world-renowned clinical, translational and health
services researcher. (Partial attendance; virtual)
- Professor Michael Bauer,
Professor and Chair of the Department of Anaesthesiology
and Intensive Care Medicine at Jena University
Hospital, Germany.
- Dr. Lieuwe Bos is Principal Investigator within the
Intensive Care department at Amsterdam UMC. He is also
an associate professor at the University of Amsterdam. (Partial attendance)
- Professor Luc de Chaisemartin is Professor of
Immunology at Paris-Cité University, and Head of the
Biological Immunology Department at Bichat Hospital,
Paris.
- Dr. Charles Dehout is an attending physician
at Erasmus Hospital in Brussels, specializing in internal medicine
and intensive care.
- Professor Evangelos J.
Giamarellos-Bourboulis, National and Kapodistrian
University of Athens, Greece
and Chair of the European Sepsis Alliance.
- Dr. Caroline Neumann is Caroline Neumann
is a Senior Consultant in Intensive Care Medicine at
Jena University Hospital, Germany.
- Dr. Andrew Retter, Clinical Lead in Critical Care
Medicine, ECMO and Thrombosis, and Chief Medical
Officer at Volition.
- Professor Mervyn Singer OBE, University College London, UK. Co-chair of the Sepsis-3
Definitions International Task Force; past-chair, International
Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior
Investigator.
Notes
- Sepsis arises when the body's response to an infection injures
its own tissues and organs. It may lead to shock, multi-organ
failure, and death – especially if not recognized early and treated
promptly. (Global Sepsis Alliance - World Sepsis Day website)
- Sepsis is the number one cause of death in hospitals worldwide
and accounts for at least 11 million deaths per year.
- September is Sepsis Awareness Month and World Sepsis
Day takes place on Friday 13th
September 2024.
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing, completion, success and delivery of data from clinical
studies, the effectiveness and availability of Volition's
blood-based diagnostic, prognostic and disease monitoring tests,
Volition's ability to develop and successfully commercialize such
test platforms for early detection of cancer and other diseases as
well as serving as a diagnostic, prognostic or disease monitoring
tools for such diseases, and Volition's success in securing
licensing and/or distribution agreements with third parties for its
products. Volition's actual results may differ materially from
those indicated in these forward-looking statements due to numerous
risks and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks,
including those identified in Volition's most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as other
documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations,
estimates and projections about Volition's business based, in part,
on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this press release, and,
except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Photo:
https://mma.prnewswire.com/media/2502647/VolitionRx.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-hosts-kol-roundtable-on-sepsis-302244942.html
SOURCE VolitionRx Limited